Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Relay Therapeutics, Inc. (RLAY)
USD19.05
-0.04 (-0.18%)
US NASDAQ Healthcare Biotechnology
Address
399 Binney Street 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
Sanjiv K. Patel
Website
relaytx.com
IPO
2020-07-16
CIK 1812364 ISIN US75943R1023
Description
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD19.05
-0.04 (-0.18%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
1.75
Float Shares
140.81M
Free Float %
74.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.62% | +0.08% | -13.45% | +46.77% | +109.56% | +52.84% | +315.76% | +26.15% | -53.17% | -63.11% | -63.11% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (15 ratings, all time)
Buy
Price Targets & DCF
Current price
19.05
Low
18.00
-5.5%
Consensus
21.60
+13.4%
Median
22.00
+15.5%
High
25.00
+31.3%
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 10 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
21.50
+12.9%
|
| Last Quarter | 5 |
21.60
+13.4%
|
| Last Year | 7 |
19.29
+1.3%
|
| All Time | 16 |
19.72
+3.5%
|
Quality scores
Altman Z-Score
21.02
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+53.4% ★ Q1'26: -60.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+31.8% ★ Q1'26: +10.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,931.9% Q1'26: -1,703.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,800.6% Q1'26: -2,619.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-614.4% Q1'26: -992.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.1% Q1'26: +6.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.12× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 7 EPS Ana. |
Dec 2027 5 Rev. Ana. 7 EPS Ana. |
Dec 2028 5 Rev. Ana. 8 EPS Ana. |
Dec 2029 2 Rev. Ana. 6 EPS Ana. |
Dec 2030 2 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
82.65M
est: 38.75M (+113.3%)
|
3.03M
est: 6.41M (-52.8%)
|
1.38M
est: 4.46M (-69.0%)
|
25.55M
est: 35.21M (-27.4%)
|
10.01M
est: 15.08M (-33.6%)
|
15.36M
est: 12.81M (+19.8%)
|
10.88M
2.50M – 16.79M
-15.1% YoY
|
19.66M
199.8K – 31.85M
+80.7% YoY
|
51.03M
4.90M – 81.14M
+159.6% YoY
|
137.03M
13.16M – 217.89M
+168.5% YoY
|
361.69M
34.74M – 575.11M
+163.9% YoY
|
| EBITDA |
-52.25M
est: -35.90M (-45.5%)
|
-223.08M
est: -574.20M (+61.1%)
|
-306.82M
est: -252.99M (-21.3%)
|
-374.15M
est: -35.21M (-962.7%)
|
-380.21M
est: -15.08M (-2,421.4%)
|
-272.92M
est: -12.81M (-2,030.2%)
|
-10.88M
-16.79M – -2.50M
+15.1% YoY
|
-19.66M
-31.85M – -199.8K
-80.7% YoY
|
-51.03M
-81.14M – -4.90M
-159.6% YoY
|
-137.03M
-217.89M – -13.16M
-168.5% YoY
|
-361.69M
-575.11M – -34.74M
-163.9% YoY
|
| EBIT |
-55.80M
est: -36.23M (-54.0%)
|
-227.01M
est: -580.17M (+60.9%)
|
-310.95M
est: -260.72M (-19.3%)
|
-379.42M
est: -35.21M (-977.7%)
|
-385.67M
est: -15.08M (-2,457.7%)
|
-276.48M
est: -12.81M (-2,058.0%)
|
-10.88M
-16.79M – -2.50M
+15.1% YoY
|
-19.66M
-31.85M – -199.8K
-80.7% YoY
|
-51.03M
-81.14M – -4.90M
-159.6% YoY
|
-137.03M
-217.89M – -13.16M
-168.5% YoY
|
-361.69M
-575.11M – -34.74M
-163.9% YoY
|
| Net Income |
-52.41M
est: -687.19M (+92.4%)
|
-363.87M
est: -579.15M (+37.2%)
|
-290.51M
est: -258.70M (-12.3%)
|
-341.97M
est: -322.83M (-5.9%)
|
-337.71M
est: -427.82M (+21.1%)
|
-276.48M
est: -272.71M (-1.4%)
|
-291.88M
-317.51M – -234.23M
-7.0% YoY
|
-301.61M
-311.09M – -262.43M
-3.3% YoY
|
-304.18M
-388.81M – -208.96M
-0.9% YoY
|
-205.62M
-363.34M – 36.01M
+32.4% YoY
|
-73.21M
-129.37M – 12.82M
+64.4% YoY
|
| SGA |
38.59M
est: 602.76M (-93.6%)
|
57.39M
est: 99.74M (-42.5%)
|
65.98M
est: 69.35M (-4.9%)
|
74.95M
est: 570.38M (-86.9%)
|
76.59M
est: 244.29M (-68.6%)
|
56.71M
est: 207.56M (-72.7%)
|
176.31M
40.54M – 272.08M
-15.1% YoY
|
318.52M
3.24M – 516.04M
+80.7% YoY
|
826.74M
79.41M – 1.31B
+159.6% YoY
|
2.22B
213.22M – 3.53B
+168.5% YoY
|
5.86B
562.79M – 9.32B
+163.9% YoY
|
| EPS |
-2.56
est: -4.81 (+46.8%)
|
-3.82
est: -3.69 (-3.6%)
|
-2.59
est: -2.74 (+5.5%)
|
-2.79
est: -2.53 (-10.4%)
|
-2.36
est: -2.51 (+5.9%)
|
-1.61
est: -1.73 (+7.0%)
|
-1.62
-1.85 – -1.37
+6.6% YoY
|
-1.66
-1.81 – -1.53
-2.7% YoY
|
-1.56
-2.27 – -1.22
+6.0% YoY
|
-1.20
-2.12 – 0.21
+23.3% YoY
|
-0.43
-0.75 – 0.07
+64.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-28 | Citizens | Market Outperform | Market Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-261.48M
OE per share TTM
-1.51
Owner's Yield
-11.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
240.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
31
Total invested
15.77M
Insider transactions (90d)
3
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SB Investment Advisers (UK) Limited | 27.90M | 31.00% | — | 27.90M | — | 27.90M | FI | — | 2021-02-16 | ↗ |
| 2 | SVF Pauling (Cayman) Limited | 27.90M | 31.00% | — | 27.90M | — | 27.90M | CO | — | 2021-02-16 | ↗ |
| 3 | SoftBank Vision Fund (AIV M2) L.P. | 27.90M | 31.00% | — | 27.90M | — | 27.90M | PN | — | 2021-02-16 | ↗ |
| 4 | FMR LLC | 11.96M | 9.95% | 11.96M | — | 11.96M | — | HC | Delaware | 2022-10-11 | ↗ |
| 5 | Casdin Capital, LLC | 6.30M | 5.16% | — | 6.30M | — | 6.30M | IA | Delaware | 2023-10-02 | ↗ |
| 6 | Casdin Partners GP, LLC | 6.30M | 5.16% | — | 6.30M | — | 6.30M | OO | Delaware | 2023-10-02 | ↗ |
| 7 | Eli Casdin | 6.30M | 5.16% | — | 6.30M | — | 6.30M | HC, IN | Delaware | 2023-10-02 | ↗ |
| 8 | STATE STREET CORPORATION | 6.26M | 5.18% | — | 6.10M | — | 6.26M | HC | — | 2023-02-03 | ↗ |
| 9 | The Vanguard Group - 23-1945930 | 6.20M | 5.74% | — | 121.0K | 6.02M | 174.5K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 10 | (1) BlackRock, Inc. | 5.99M | 5.50% | 5.86M | — | 5.99M | — | HC | Delaware | 2022-02-04 | ↗ |
| 11 | Abigail P. Johnson | 4.76M | 5.29% | — | — | 4.76M | — | IN | United States of America | 2021-02-08 | ↗ |
| 12 | Kevin P. Starr | 362.6K | 0.30% | 362.6K | — | 362.6K | — | IN | — | 2022-02-14 | ↗ |
| 13 | Mark Levin | 324.7K | 0.30% | 324.7K | — | 324.7K | — | IN | — | 2022-02-14 | ↗ |
| 14 | Robert I. Tepper | 322.9K | 0.30% | 322.9K | — | 322.9K | — | IN | — | 2022-02-14 | ↗ |
| 15 | TRV GP III, LLC | — | 0.00% | — | — | — | — | OO | — | 2022-02-14 | ↗ |
| 16 | TRV GP IV, LLC | — | 0.00% | — | — | — | — | OO | — | 2022-02-14 | ↗ |
| 17 | Third Rock Ventures GP III, L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-14 | ↗ |
| 18 | Third Rock Ventures GP IV, L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-14 | ↗ |
| 19 | Third Rock Ventures III, L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-14 | ↗ |
| 20 | Third Rock Ventures IV, L.P. | — | 0.00% | — | — | — | — | PN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
31
-197 vs prev Q
New positions
4
Closed positions
197
Increased
17
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 901.5K +901.5K (+100.0%) | 7.63B +7.6B (+100.0%) | 0.52% +0.523 pp | 7.54% +7.543 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 2 | SB INVESTMENT ADVISERS (UK) LTD | 27.90M +— (+0.0%) | 236.08M +90.4M (+62.1%) | 16.19% -0.106 pp | 2.36% +1.263 pp | USD42.59 -80.1% | 22 qtrs — |
| 3 | COMMODORE CAPITAL LP | 17.00M +— (+0.0%) | 143.82M +55.1M (+62.1%) | 9.86% -0.065 pp | 9.57% +5.242 pp | USD3.84 +120.3% | 3 qtrs — |
| 4 | POINT72 ASSET MANAGEMENT, L.P. | 13.86M -914.5K (-6.2%) | 117.25M +40.1M (+52.0%) | 8.04% -0.587 pp | 0.13% +0.002 pp | USD3.43 +146.6% | 11 qtrs — |
| 5 | BLACKROCK, INC. | 13.23M -530.9K (-3.9%) | 111.91M +40.1M (+55.8%) | 7.67% -0.360 pp | 0.00% +0.001 pp | USD6.49 +30.4% | 6 qtrs — |
| 6 | CASDIN CAPITAL, LLC | 13.00M +1.7M (+14.7%) | 110.01M +50.8M (+85.8%) | 7.54% +0.921 pp | 6.83% +1.897 pp | USD15.57 -45.7% | 22 qtrs — |
| 7 | VANGUARD GROUP INC | 9.69M +295.7K (+3.1%) | 81.99M +32.9M (+67.2%) | 5.62% +0.136 pp | 0.00% +0.001 pp | USD21.34 -60.4% | 22 qtrs — |
| 8 | BELLEVUE GROUP AG | 8.35M -246.0 (0.0%) | 70.60M +27.0M (+62.1%) | 4.84% -0.032 pp | 1.34% +0.433 pp | USD21.38 -60.4% | 22 qtrs — |
| 9 | STATE STREET CORP | 6.43M +1.4M (+26.8%) | 54.36M +27.9M (+105.6%) | 3.73% +0.770 pp | 0.00% +0.001 pp | USD14.57 -41.9% | 22 qtrs — |
| 10 | NEXTECH INVEST, LTD. | 4.70M +855.1K (+22.2%) | 39.77M +19.7M (+98.1%) | 2.73% +0.481 pp | 3.85% +0.789 pp | USD3.68 +129.9% | 4 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 3.41M +354.8K (+11.6%) | 28.85M +12.9M (+80.9%) | 1.98% +0.194 pp | 0.00% +0.001 pp | USD19.06 -55.6% | 22 qtrs — |
| 12 | TCG CROSSOVER MANAGEMENT, LLC | 3.22M +1.4M (+77.9%) | 27.24M +17.8M (+188.3%) | 1.87% +0.811 pp | 0.90% +0.437 pp | USD6.64 +27.4% | 2 qtrs — |
| 13 | DIMENSIONAL FUND ADVISORS LP | 2.48M -2.6K (-0.1%) | 20.98M +8.0M (+61.9%) | 1.44% -0.011 pp | 0.00% +0.002 pp | USD9.87 -14.3% | 16 qtrs — |
| 14 | BIOIMPACT CAPITAL LLC | 2.23M -50.2K (-2.2%) | 18.89M +7.0M (+58.5%) | 1.30% -0.038 pp | 2.16% +0.211 pp | USD9.86 -14.2% | 12 qtrs — |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | 2.10M +924.9K (+78.7%) | 17.77M +11.6M (+189.7%) | 1.22% +0.532 pp | 0.02% +0.015 pp | USD6.65 +27.2% | 13 qtrs — |
| 16 | MORGAN STANLEY | 2.02M +254.4K (+14.4%) | 17.08M +7.9M (+85.4%) | 1.17% +0.141 pp | 0.00% +0.001 pp | USD8.11 +4.3% | 22 qtrs — |
| 17 | PERCEPTIVE ADVISORS LLC | 1.90M +1.9M (+100.0%) | 16.10M +16.1M (+100.0%) | 1.10% +1.104 pp | 0.29% +0.287 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 18 | GOLDMAN SACHS GROUP INC | 1.86M -9.2K (-0.5%) | 15.73M +6.0M (+61.3%) | 1.08% -0.013 pp | 0.00% +0.001 pp | USD10.68 -20.8% | 22 qtrs — |
| 19 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.65M +507.7K (+44.6%) | 13.92M +8.0M (+134.4%) | 0.95% +0.290 pp | 0.00% +0.001 pp | USD17.69 -52.2% | 22 qtrs — |
| 20 | ALPHABET INC. | 1.57M +— (+0.0%) | 13.27M +5.1M (+62.1%) | 0.91% -0.006 pp | 0.51% +0.175 pp | USD41.71 -79.7% | 22 qtrs — |
| 21 | TWO SIGMA INVESTMENTS, LP | 1.56M +464.6K (+42.4%) | 13.20M +7.5M (+130.8%) | 0.91% +0.265 pp | 0.02% +0.010 pp | USD7.23 +17.0% | 10 qtrs — |
| 22 | KYNAM CAPITAL MANAGEMENT, LP | 1.42M -1.5M (-50.7%) | 12.05M -3.0M (-20.0%) | 0.83% -0.860 pp | 0.77% -0.352 pp | USD3.11 +172.0% | 5 qtrs — |
| 23 | TWO SIGMA ADVISERS, LP | 1.29M +165.5K (+14.7%) | 10.91M +5.0M (+85.9%) | 0.75% +0.092 pp | 0.02% +0.010 pp | USD6.26 +35.1% | 14 qtrs — |
| 24 | AQR CAPITAL MANAGEMENT LLC | 1.16M -137.9K (-10.6%) | 9.84M +3.0M (+44.9%) | 0.67% -0.085 pp | 0.01% +0.001 pp | USD3.95 +114.2% | 9 qtrs — |
| 25 | BAKER BROS. ADVISORS LP | 1.16M +— (+0.0%) | 9.81M +3.8M (+62.1%) | 0.67% -0.004 pp | 0.06% +0.014 pp | USD13.52 -37.4% | 12 qtrs — |
| 26 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 1.14M +1.1M (+100.0%) | 9.66M +9.7M (+100.0%) | 0.66% +0.662 pp | 0.08% +0.076 pp | USD8.46 +0.0% | 3 qtrs — |
| 27 | NORTHERN TRUST CORP | 1.14M -26.7K (-2.3%) | 9.63M +3.5M (+58.3%) | 0.66% -0.020 pp | 0.00% +0.000 pp | USD23.16 -63.5% | 22 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.14M +25.4K (+2.3%) | 9.62M +3.8M (+65.8%) | 0.66% +0.011 pp | 0.00% +0.001 pp | USD20.25 -58.2% | 22 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 1.04M -154.9K (-13.0%) | 8.81M +2.6M (+41.1%) | 0.60% -0.094 pp | 0.00% +0.000 pp | USD5.63 +50.3% | 22 qtrs — |
| 30 | FORESITE CAPITAL MANAGEMENT IV, LLC | 1.00M +— (+0.0%) | 8.46M +3.2M (+62.1%) | 0.58% -0.004 pp | 3.68% +0.824 pp | USD7.08 +19.5% | 6 qtrs — |
| 31 | MILLENNIUM MANAGEMENT LLC | 896.9K +152.9K (+20.5%) | 7.59M +3.7M (+95.4%) | 0.52% +0.086 pp | 0.00% +0.002 pp | USD5.70 +48.4% | 21 qtrs — |
| 32 | INVESCO LTD. | 865.5K +504.3K (+139.6%) | 7.32M +5.4M (+288.3%) | 0.50% +0.291 pp | 0.00% +0.001 pp | USD8.63 -2.0% | 21 qtrs — |
| 33 | NORGES BANK | 837.4K +837.4K (+100.0%) | 7.08M +7.1M (+100.0%) | 0.49% +0.486 pp | 0.00% +0.001 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 34 | WOODLINE PARTNERS LP | 679.1K -339.0K (-33.3%) | 5.75M +430.8K (+8.1%) | 0.39% -0.201 pp | 0.02% -0.003 pp | USD8.68 -2.5% | 22 qtrs — |
| 35 | RENAISSANCE TECHNOLOGIES LLC | 647.9K -375.2K (-36.7%) | 5.48M +140.6K (+2.6%) | 0.38% -0.222 pp | 0.01% +0.002 pp | USD4.91 +72.3% | 18 qtrs — |
| 36 | ALLIANZ ASSET MANAGEMENT GMBH | 560.3K +560.3K (+100.0%) | 4.74M +4.7M (+100.0%) | 0.33% +0.325 pp | 0.00% +0.005 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 37 | HIGHVISTA STRATEGIES LLC | 545.1K +304.6K (+126.7%) | 4.61M +3.4M (+267.4%) | 0.32% +0.176 pp | 1.19% +0.880 pp | USD6.55 +29.2% | 3 qtrs — |
| 38 | ARROWMARK COLORADO HOLDINGS LLC | 541.1K +— (+0.0%) | 4.58M +1.8M (+62.1%) | 0.31% -0.002 pp | 0.10% +0.048 pp | USD21.87 -61.3% | 22 qtrs — |
| 39 | CAPTION MANAGEMENT, LLC | 500.1K +500.1K (+100.0%) | 4.23M +4.2M (+100.0%) | 0.29% +0.290 pp | 0.03% +0.029 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 40 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 500.0K +500.0K (+100.0%) | 4.23M +4.2M (+100.0%) | 0.29% +0.290 pp | 0.01% +0.006 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 41 | EVERSEPT PARTNERS, LP | 489.1K +10.1K (+2.1%) | 4.14M +1.6M (+65.5%) | 0.28% +0.004 pp | 0.21% +0.036 pp | USD3.56 +137.6% | 3 qtrs — |
| 42 | TREXQUANT INVESTMENT LP | 472.0K +472.0K (+100.0%) | 3.99M +4.0M (+100.0%) | 0.27% +0.274 pp | 0.04% +0.036 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 43 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 460.0K +— (+0.0%) | 3.89M +1.5M (+62.1%) | 0.27% -0.002 pp | 0.36% +0.098 pp | USD10.00 -15.4% | 13 qtrs — |
| 44 | BESSEMER GROUP INC | 457.9K -126.6K (-21.7%) | 3.87M +823.0K (+27.0%) | 0.27% -0.076 pp | 0.01% +0.001 pp | USD41.84 -79.8% | 22 qtrs — |
| 45 | ACADIAN ASSET MANAGEMENT LLC | 456.6K -44.6K (-8.9%) | 3.86M +1.2M (+47.7%) | 0.26% -0.028 pp | 0.01% +0.002 pp | USD2.79 +203.2% | 5 qtrs — |
| 46 | HUDSON BAY CAPITAL MANAGEMENT LP | 451.5K +451.5K (+100.0%) | 3.82M +3.8M (+100.0%) | 0.26% +0.262 pp | 0.01% +0.013 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 47 | AMERICAN CENTURY COMPANIES INC | 432.5K +38.8K (+9.9%) | 3.66M +1.6M (+78.0%) | 0.25% +0.021 pp | 0.00% +0.001 pp | USD10.07 -16.0% | 22 qtrs — |
| 48 | JPMORGAN CHASE & CO | 426.0K -36.4K (-7.9%) | 3.60M +1.2M (+49.3%) | 0.25% -0.023 pp | 0.00% +0.000 pp | USD18.38 -54.0% | 22 qtrs — |
| 49 | CONGRESS ASSET MANAGEMENT CO /MA | 414.2K +5.3K (+1.3%) | 3.50M +1.4M (+64.2%) | 0.24% +0.002 pp | 0.02% +0.011 pp | USD7.78 +8.7% | 11 qtrs — |
| 50 | BARCLAYS PLC | 414.1K +162.3K (+64.5%) | 3.50M +1.7M (+96.5%) | 0.24% +0.093 pp | 0.00% +0.000 pp | USD7.44 +13.7% | 16 qtrs — |
| 51 | SILVERARC CAPITAL MANAGEMENT, LLC | 398.2K +398.2K (+100.0%) | 3.37M +3.4M (+100.0%) | 0.23% +0.231 pp | 0.47% +0.468 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 52 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 389.6K +389.6K (+100.0%) | 3.30M +3.3M (+100.0%) | 0.23% +0.226 pp | 0.01% +0.009 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 53 | BANK OF NEW YORK MELLON CORP | 378.7K +7.1K (+1.9%) | 3.20M +1.3M (+65.2%) | 0.22% +0.003 pp | 0.00% +0.000 pp | USD21.95 -61.5% | 22 qtrs — |
| 54 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 339.1K +— (+0.0%) | 2.87M +1.1M (+62.1%) | 0.20% -0.001 pp | 0.04% +0.016 pp | USD3.98 +112.6% | 3 qtrs — |
| 55 | NUVEEN, LLC | 300.5K +12.0K (+4.2%) | 2.54M +1.0M (+68.8%) | 0.17% +0.006 pp | 0.00% +0.000 pp | USD2.85 +196.8% | 4 qtrs — |
| 56 | UBS GROUP AG | 296.0K +143.8K (+94.4%) | 2.50M +1.7M (+215.1%) | 0.17% +0.083 pp | 0.00% +0.000 pp | USD8.18 +3.4% | 22 qtrs — |
| 57 | RAYMOND JAMES FINANCIAL INC | 259.4K +44.6K (+20.8%) | 2.19M +1.1M (+95.7%) | 0.15% +0.025 pp | 0.00% +0.000 pp | USD4.95 +70.9% | 5 qtrs — |
| 58 | RAIFFEISEN BANK INTERNATIONAL AG | 250.0K +30.0K (+13.6%) | 2.09M +945.7K (+82.8%) | 0.15% +0.017 pp | 0.03% +0.012 pp | USD4.82 +75.5% | 5 qtrs — |
| 59 | SWISS NATIONAL BANK | 238.0K +5.3K (+2.3%) | 2.01M +798.8K (+65.8%) | 0.14% +0.002 pp | 0.00% +0.001 pp | USD21.04 -59.8% | 21 qtrs — |
| 60 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 222.9K +86.0K (+62.9%) | 1.89M +1.2M (+163.9%) | 0.13% +0.049 pp | 0.00% +0.000 pp | USD5.67 +49.2% | 21 qtrs — |
| 61 | SG AMERICAS SECURITIES, LLC | 220.9K +189.0K (+591.7%) | 1.87M +1.7M (+1,019.2%) | 0.13% +0.110 pp | 0.00% +0.002 pp | USD8.11 +4.3% | 6 qtrs — |
| 62 | RHUMBLINE ADVISERS | 215.7K -1.9K (-0.9%) | 1.83M +689.3K (+60.7%) | 0.13% -0.002 pp | 0.00% +0.001 pp | USD19.07 -55.6% | 22 qtrs — |
| 63 | UBS ASSET MANAGEMENT AMERICAS INC | 209.8K +7.6K (+3.8%) | 1.78M +719.6K (+68.2%) | 0.12% +0.004 pp | 0.00% +0.000 pp | USD16.10 -47.5% | 22 qtrs — |
| 64 | RAFFERTY ASSET MANAGEMENT, LLC | 193.8K +42.2K (+27.8%) | 1.64M +848.0K (+107.2%) | 0.11% +0.024 pp | 0.01% +0.003 pp | USD11.62 -27.2% | 21 qtrs — |
| 65 | ADVISOR GROUP HOLDINGS, INC. | 186.4K +— (+0.0%) | 1.58M +606.8K (+62.6%) | 0.11% -0.001 pp | 0.00% +0.001 pp | USD5.24 +61.5% | 20 qtrs — |
| 66 | TD ASSET MANAGEMENT INC | 182.0K +63.7K (+53.9%) | 1.54M +922.3K (+149.4%) | 0.11% +0.037 pp | 0.00% +0.001 pp | USD12.15 -30.4% | 22 qtrs — |
| 67 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 177.5K +15.0K (+9.2%) | 1.49M +638.7K (+75.3%) | 0.10% +0.008 pp | 0.00% +0.001 pp | USD19.31 -56.2% | 22 qtrs — |
| 68 | IEQ CAPITAL, LLC | 162.3K -34.2K (-17.4%) | 1.37M +347.4K (+33.9%) | 0.09% -0.021 pp | 0.00% +0.001 pp | USD3.37 +151.0% | 4 qtrs — |
| 69 | FMR LLC | 162.2K -520.0 (-0.3%) | 1.37M +522.9K (+61.6%) | 0.09% -0.001 pp | 0.00% +0.000 pp | USD10.03 -15.7% | 22 qtrs — |
| 70 | WELLS FARGO & COMPANY/MN | 157.9K +56.4K (+55.5%) | 1.34M +805.7K (+152.0%) | 0.09% +0.032 pp | 0.00% +0.000 pp | USD7.82 +8.2% | 22 qtrs — |
| 71 | XTX TOPCO LTD | 157.4K +157.4K (+100.0%) | 1.33M +1.3M (+100.0%) | 0.09% +0.091 pp | 0.04% +0.035 pp | USD8.46 +0.0% | 13 qtrs — |
| 72 | ALGERT GLOBAL LLC | 146.5K -262.3K (-64.2%) | 1.24M -895.0K (-41.9%) | 0.09% -0.154 pp | 0.02% -0.016 pp | USD6.36 +33.0% | 13 qtrs — |
| 73 | ALLIANCEBERNSTEIN L.P. | 145.3K +— (+0.0%) | 1.23M +470.6K (+62.1%) | 0.08% -0.001 pp | 0.00% +0.000 pp | USD11.16 -24.2% | 22 qtrs — |
| 74 | ALPS ADVISORS INC | 142.3K +59.9K (+72.7%) | 1.20M +773.8K (+179.8%) | 0.08% +0.034 pp | 0.01% +0.005 pp | USD5.56 +52.2% | 3 qtrs — |
| 75 | SANCTUARY ADVISORS, LLC | 142.2K +142.2K (+100.0%) | 1.20M +1.2M (+100.0%) | 0.08% +0.083 pp | 0.01% +0.007 pp | USD8.46 +0.0% | 3 qtrs — |
| 76 | DEUTSCHE BANK AG\ | 124.0K +3.8K (+3.2%) | 1.05M +421.6K (+67.2%) | 0.07% +0.002 pp | 0.00% +0.000 pp | USD9.19 -7.9% | 22 qtrs — |
| 77 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 117.7K -20.9K (-15.1%) | 995.5K +272.3K (+37.7%) | 0.07% -0.013 pp | 0.00% +0.000 pp | USD20.32 -58.4% | 22 qtrs — |
| 78 | CITADEL ADVISORS LLC | 114.1K +114.1K (+100.0%) | 965.6K +965.6K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 79 | NEOS INVESTMENT MANAGEMENT LLC | 113.2K +19.8K (+21.1%) | 957.9K +470.0K (+96.3%) | 0.07% +0.011 pp | 0.01% +0.002 pp | USD6.55 +29.2% | 9 qtrs — |
| 80 | TEMA ETFS LLC | 111.6K +18.1K (+19.4%) | 943.8K +455.9K (+93.4%) | 0.06% +0.010 pp | 0.07% +0.033 pp | USD4.46 +89.7% | 5 qtrs — |
| 81 | LEGAL & GENERAL GROUP PLC | 109.2K -3.1K (-2.8%) | 923.9K +337.6K (+57.6%) | 0.06% -0.002 pp | 0.00% +0.000 pp | USD20.00 -57.7% | 22 qtrs — |
| 82 | HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 105.0K +105.0K (+100.0%) | 887.9K +887.9K (+100.0%) | 0.06% +0.061 pp | 0.05% +0.055 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 83 | STATE OF WISCONSIN INVESTMENT BOARD | 101.2K +19.8K (+24.3%) | 855.8K +431.0K (+101.5%) | 0.06% +0.011 pp | 0.00% +0.001 pp | USD5.85 +44.6% | 22 qtrs — |
| 84 | ICONIQ CAPITAL, LLC | 94.7K +— (+0.0%) | 801.1K +306.8K (+62.1%) | 0.05% 0.000 pp | 0.01% +0.006 pp | USD42.59 -80.1% | 22 qtrs — |
| 85 | SQUAREPOINT OPS LLC | 94.2K +94.2K (+100.0%) | 797.0K +797.0K (+100.0%) | 0.05% +0.055 pp | 0.00% +0.001 pp | USD8.46 +0.0% | 7 qtrs — |
| 86 | MAN GROUP PLC | 87.0K -100.8K (-53.7%) | 736.3K -244.1K (-24.9%) | 0.05% -0.059 pp | 0.00% -0.001 pp | USD3.75 +125.6% | 9 qtrs — |
| 87 | CREATIVE PLANNING | 85.8K +6.0K (+7.5%) | 726.2K +309.2K (+74.2%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD4.13 +104.8% | 5 qtrs — |
| 88 | TUDOR INVESTMENT CORP ET AL | 84.2K +7.7K (+10.1%) | 712.0K +313.0K (+78.4%) | 0.05% +0.004 pp | 0.00% +0.001 pp | USD5.52 +53.3% | 10 qtrs — |
| 89 | JUMP FINANCIAL, LLC | 82.6K +82.6K (+100.0%) | 698.4K +698.4K (+100.0%) | 0.05% +0.048 pp | 0.01% +0.009 pp | USD8.46 +0.0% | 13 qtrs — |
| 90 | ENGINEERS GATE MANAGER LP | 78.4K +78.4K (+100.0%) | 663.0K +663.0K (+100.0%) | 0.05% +0.046 pp | 0.01% +0.008 pp | USD8.46 +0.0% | 13 qtrs — |
| 91 | METLIFE INVESTMENT MANAGEMENT, LLC | 77.5K +14.3K (+22.7%) | 656.0K +326.0K (+98.8%) | 0.05% +0.008 pp | 0.00% +0.002 pp | USD17.56 -51.8% | 22 qtrs — |
| 92 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 76.7K +6.7K (+9.5%) | 647.5K +282.1K (+77.2%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD5.98 +41.5% | 7 qtrs — |
| 93 | JANE STREET GROUP, LLC | 76.5K -108.5K (-58.7%) | 647.0K -318.5K (-33.0%) | 0.04% -0.064 pp | 0.00% +0.000 pp | USD5.22 +62.1% | 20 qtrs — |
| 94 | PROFUND ADVISORS LLC | 72.6K +38.9K (+115.4%) | 614.1K +438.2K (+249.1%) | 0.04% +0.022 pp | 0.02% +0.013 pp | USD9.70 -12.8% | 12 qtrs — |
| 95 | CWM, LLC | 67.6K -325.0 (-0.5%) | 572.0K +217.0K (+61.1%) | 0.04% 0.000 pp | 0.00% +0.001 pp | USD3.62 +133.7% | 7 qtrs — |
| 96 | J. GOLDMAN & CO LP | 67.6K +67.6K (+100.0%) | 571.9K +571.9K (+100.0%) | 0.04% +0.039 pp | 0.02% +0.015 pp | USD8.46 +0.0% | 1 qtrs NEW |
| 97 | JAIN GLOBAL LLC | 66.6K +66.6K (+100.0%) | 563.3K +563.3K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.003 pp | USD8.46 +0.0% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 115 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Dorsey Wright Healthcare Momentum ETF PTH | 2.32% | 3.92M | 0.72% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 2.23% | 4.74M | 0.50% |
| 3 | Tema Oncology ETF CANC | 1.84% | 2.61M | 0.75% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 1.17% | 419.9K | 0.45% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 1.17% | 126.47M | 0.35% |
| 6 | Fidelity Disruptive Medicine ETF FMED | 1.02% | 471.9K | 0.50% |
| 7 | Virtus Biotech Clinical Trials ETF BBC | 0.83% | 478.6K | 0.65% |
| 8 | Invesco Dorsey Wright SmallCap Momentum ETF DWAS | 0.71% | 3.34M | 0.60% |
| 9 | Harbor Health Care ETF (MEDI) MEDI | 0.65% | 282.8K | 0.80% |
| 10 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.36% | 4.10M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.17
Bearish
Ratio by volume
0.07
Bearish
Buys
1
Sells
6
Shares acquired
1.8K
Shares disposed
24.5K
Cash buys
—
Cash sales
5.00
Net activity
-22,732
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 753 | 14.79 | 11.1K | 275,857 | D | ↗ |
| 2026-04-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 972 | 14.79 | 14.4K | 212,895 | D | ↗ |
| 2026-04-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 1,490 | 14.79 | 22.0K | 418,557 | D | ↗ |
| 2026-04-09 | Catinazzo Thomas | Officer | M-Exempt | A | Common Stock | 1,800 | 5.22 | 9.4K | 215,667 | D | ↗ |
| 2026-04-07 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 17,717 | 13.01 | 230.5K | 213,867 | D | ↗ |
| 2026-03-09 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 17,717 | 10.06 | 178.2K | 231,584 | D | ↗ |
| 2026-01-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,354 | 8.45 | 11.4K | 276,610 | D | ↗ |
| 2026-01-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 1,695 | 8.45 | 14.3K | 249,301 | D | ↗ |
| 2026-01-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 2,686 | 8.45 | 22.7K | 420,047 | D | ↗ |
| 2026-01-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 11,684 | 7.62 | 89.0K | 277,964 | D | ↗ |
| 2026-01-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 13,820 | 7.62 | 105.3K | 250,996 | D | ↗ |
| 2026-01-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 18,895 | 7.62 | 144.0K | 422,733 | D | ↗ |
| 2026-01-13 | Rahmer Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 475,000 | 7.94 | 3.77M | 475,000 | D | ↗ |
| 2026-01-13 | Patel Sanjiv | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,450,000 | 7.94 | 11.51M | 1,450,000 | D | ↗ |
| 2026-01-13 | Catinazzo Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 7.94 | 3.18M | 400,000 | D | ↗ |
| 2026-01-13 | Bergstrom Donald A | Officer | A-Award | A | Stock Option (Right to Buy) | 575,000 | 7.94 | 4.57M | 575,000 | D | ↗ |
| 2026-01-06 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 43,168 | 7.82 | 337.6K | 661,041 | D | ↗ |
| 2025-12-31 | Rahmer Peter | Officer | A-Award | A | Common Stock | 994 | 2.99 | 3.0K | 338,463 | D | ↗ |
| 2025-12-31 | Patel Sanjiv | Director / Officer | A-Award | A | Common Stock | 994 | 2.99 | 3.0K | 704,209 | D | ↗ |
| 2025-11-04 | Dable Habib J | Director | A-Award | A | Stock Option (Right to Buy) | 207,931 | 6.86 | 1.43M | 207,931 | D | ↗ |
| 2025-11-04 | COATS LONNEL | Director | A-Award | A | Stock Option (Right to Buy) | 207,931 | 6.86 | 1.43M | 207,931 | D | ↗ |
| 2025-11-03 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 62,073 | 7.00 | 434.5K | 703,215 | D | ↗ |
| 2025-10-29 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 21,394 | 7.50 | 160.5K | 337,469 | D | ↗ |
| 2025-10-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 19,135 | 7.29 | 139.5K | 358,863 | D | ↗ |
| 2025-10-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 21,664 | 7.29 | 157.9K | 313,631 | D | ↗ |
| 2025-10-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 30,897 | 7.29 | 225.2K | 521,823 | D | ↗ |
| 2025-07-29 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 15,724 | 3.68 | 57.9K | 377,998 | D | ↗ |
| 2025-07-29 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 18,380 | 3.68 | 67.6K | 335,295 | D | ↗ |
| 2025-07-29 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 26,701 | 3.68 | 98.3K | 552,720 | D | ↗ |
| 2025-07-29 | Adams Brian | Officer | S-Sale | D | Common Stock | 18,276 | 3.68 | 67.3K | 371,472 | D | ↗ |
| 2025-07-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,359 | 3.74 | 5.1K | 393,722 | D | ↗ |
| 2025-07-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 1,701 | 3.74 | 6.4K | 353,675 | D | ↗ |
| 2025-07-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 4,069 | 3.74 | 15.2K | 579,421 | D | ↗ |
| 2025-07-28 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,637 | 3.74 | 6.1K | 389,748 | D | ↗ |
| 2025-07-09 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 42,740 | 3.57 | 152.6K | 783,927 | D | ↗ |
| 2025-06-30 | Rahmer Peter | Officer | A-Award | A | Common Stock | 5,000 | 2.94 | 14.7K | 395,081 | D | ↗ |
| 2025-06-30 | Patel Sanjiv | Director / Officer | A-Award | A | Common Stock | 5,000 | 2.94 | 14.7K | 826,667 | D | ↗ |
| 2025-06-09 | Mazumdar Claire | Director | A-Award | A | Stock Option (Right to Buy) | 421,241 | 3.36 | 1.42M | 421,241 | D | ↗ |
| 2025-06-06 | Rubin Jami | Director | A-Award | A | Stock Option (Right to Buy) | 136,681 | 3.36 | 459.2K | 136,681 | D | ↗ |
| 2025-06-06 | Murcko Mark | Director | A-Award | A | Stock Option (Right to Buy) | 136,681 | 3.36 | 459.2K | 136,681 | D | ↗ |
| 2025-06-06 | Kathiresan Sekar | Director | A-Award | A | Stock Option (Right to Buy) | 136,681 | 3.36 | 459.2K | 136,681 | D | ↗ |
| 2025-06-06 | INGRAM DOUGLAS S | Director | A-Award | A | Stock Option (Right to Buy) | 136,681 | 3.36 | 459.2K | 136,681 | D | ↗ |
| 2025-06-06 | HILL LINDA A | Director | A-Award | A | Stock Option (Right to Buy) | 136,681 | 3.36 | 459.2K | 136,681 | D | ↗ |
| 2025-06-06 | Borisy Alexis | Director | A-Award | A | Stock Option (Right to Buy) | 136,681 | 3.36 | 459.2K | 136,681 | D | ↗ |
| 2025-04-30 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 10,739 | 3.00 | 32.2K | 390,081 | D | ↗ |
| 2025-04-30 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 12,943 | 3.00 | 38.8K | 355,376 | D | ↗ |
| 2025-04-30 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 27,472 | 3.00 | 82.4K | 583,490 | D | ↗ |
| 2025-04-30 | Adams Brian | Officer | S-Sale | D | Common Stock | 12,943 | 3.00 | 38.8K | 391,385 | D | ↗ |
| 2025-04-29 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 3,558 | 3.23 | 11.5K | 368,319 | D | ↗ |
| 2025-04-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,364 | 3.17 | 4.3K | 400,820 | D | ↗ |
| 2025-04-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 1,709 | 3.17 | 5.4K | 372,858 | D | ↗ |
| 2025-04-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 4,090 | 3.17 | 13.0K | 610,962 | D | ↗ |
| 2025-04-28 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,644 | 3.17 | 5.2K | 404,328 | D | ↗ |
| 2025-04-23 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 42,769 | 2.97 | 127.0K | 840,320 | D | ↗ |
| 2025-03-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 247 | 2.84 | 701.48 | 402,184 | D | ↗ |
| 2025-03-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 298 | 2.84 | 846.32 | 379,133 | D | ↗ |
| 2025-03-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 986 | 2.84 | 2.8K | 615,052 | D | ↗ |
| 2025-03-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 298 | 2.84 | 846.32 | 405,972 | D | ↗ |
| 2025-02-13 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 75,324 | 3.70 | 278.7K | 883,089 | D | ↗ |
| 2025-02-11 | Patel Sanjiv | Director / Officer | A-Award | A | Common Stock | 332,465 | 0.00 | — | 958,413 | D | ↗ |
| 2025-01-30 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 17,250 | 4.42 | 76.2K | 402,431 | D | ↗ |
| 2025-01-30 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 20,791 | 4.42 | 91.9K | 379,431 | D | ↗ |
| 2025-01-30 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 30,823 | 4.42 | 136.2K | 616,038 | D | ↗ |
| 2025-01-30 | Adams Brian | Officer | S-Sale | D | Common Stock | 20,791 | 4.42 | 91.9K | 406,270 | D | ↗ |
| 2025-01-29 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 26,541 | 4.55 | 120.8K | 419,681 | D | ↗ |
| 2025-01-29 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 2,109 | 4.55 | 9.6K | 400,222 | D | ↗ |
| 2025-01-29 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 46,407 | 4.55 | 211.2K | 646,861 | D | ↗ |
| 2025-01-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,673 | 4.63 | 7.7K | 307,081 | D | ↗ |
| 2025-01-28 | Catinazzo Thomas | Officer | A-Award | A | Common Stock | 139,141 | 0.00 | — | 402,331 | D | ↗ |
| 2025-01-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 3,220 | 4.63 | 14.9K | 516,868 | D | ↗ |
| 2025-01-28 | Adams Brian | Officer | A-Award | A | Common Stock | 139,141 | 0.00 | — | 427,061 | D | ↗ |
| 2025-01-23 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 125,000 | 4.78 | 597.5K | 199,548 | I | ↗ |
| 2025-01-22 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 125,000 | 4.80 | 600.0K | 324,548 | I | ↗ |
| 2025-01-21 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 125,000 | 4.52 | 565.0K | 449,548 | I | ↗ |
| 2025-01-10 | Rahmer Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 4.45 | 1.22M | 275,000 | D | ↗ |
| 2025-01-10 | Patel Sanjiv | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,105,000 | 4.45 | 4.92M | 1,105,000 | D | ↗ |
| 2025-01-10 | Catinazzo Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 4.45 | 1.22M | 275,000 | D | ↗ |
| 2025-01-10 | Bergstrom Donald A | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 4.45 | 1.78M | 400,000 | D | ↗ |
| 2025-01-10 | Adams Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 4.45 | 1.22M | 275,000 | D | ↗ |
| 2025-01-06 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 16,576 | 4.45 | 73.8K | 308,754 | D | ↗ |
| 2025-01-03 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 32,177 | 4.30 | 138.4K | 325,330 | D | ↗ |
| 2025-01-02 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 32,156 | 4.15 | 133.4K | 357,507 | D | ↗ |
| 2024-12-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 400 | 4.38 | 1.8K | 389,663 | D | ↗ |
| 2024-12-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 299 | 4.38 | 1.3K | 303,792 | D | ↗ |
| 2024-12-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 657 | 4.38 | 2.9K | 520,088 | D | ↗ |
| 2024-12-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 299 | 4.38 | 1.3K | 321,608 | D | ↗ |
| 2024-12-16 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 100,000 | 5.00 | 500.0K | 574,548 | I | ↗ |
| 2024-10-29 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 2,300 | 5.95 | 13.7K | 304,091 | D | ↗ |
| 2024-10-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,621 | 6.06 | 9.8K | 390,063 | D | ↗ |
| 2024-10-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 5,105 | 6.06 | 30.9K | 306,391 | D | ↗ |
| 2024-10-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 2,688 | 6.06 | 16.3K | 520,745 | D | ↗ |
| 2024-10-28 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,632 | 6.06 | 9.9K | 321,907 | D | ↗ |
| 2024-09-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 245 | 7.51 | 1.8K | 391,684 | D | ↗ |
| 2024-09-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 295 | 7.51 | 2.2K | 319,355 | D | ↗ |
| 2024-09-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 648 | 7.51 | 4.9K | 523,433 | D | ↗ |
| 2024-09-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 295 | 7.51 | 2.2K | 323,539 | D | ↗ |
| 2024-07-31 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 13,708 | 8.19 | 112.3K | 391,929 | — | ↗ |
| 2024-07-30 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 15,128 | 8.28 | 125.3K | 405,637 | — | ↗ |
| 2024-07-29 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 12,164 | 8.51 | 103.5K | 420,765 | — | ↗ |
| 2024-07-29 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 9,078 | 8.51 | 77.3K | 319,650 | — | ↗ |
| 2024-07-29 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 2,698 | 8.85 | 23.9K | 524,081 | — | ↗ |
| 2024-07-29 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,638 | 8.85 | 14.5K | 323,834 | — | ↗ |
| 2024-07-26 | Patel Sanjiv | Director / Officer | M-Exempt | A | Common Stock | 36,706 | 5.04 | 185.0K | 802,836 | — | ↗ |
| 2024-07-25 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 50,000 | 9.16 | 458.0K | 766,130 | — | ↗ |
| 2024-06-30 | Rahmer Peter | Officer | A-Award | A | Common Stock | 2,108 | 5.54 | 11.7K | 434,288 | — | ↗ |
| 2024-06-30 | Patel Sanjiv | Director / Officer | A-Award | A | Common Stock | 2,108 | 5.54 | 11.7K | 766,130 | — | ↗ |
| 2024-06-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 245 | 6.26 | 1.5K | 432,180 | — | ↗ |
| 2024-06-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 9,078 | 6.24 | 56.6K | 330,430 | — | ↗ |
| 2024-06-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 648 | 6.26 | 4.1K | 526,779 | — | ↗ |
| 2024-06-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 295 | 6.26 | 1.8K | 325,472 | — | ↗ |
| 2024-06-10 | Rubin Jami | Director | M-Exempt | A | Common Stock | 42,242 | 5.04 | 212.9K | 67,242 | — | ↗ |
| 2024-06-05 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 20,450 | 7.06 | 144.4K | 432,425 | — | ↗ |
| 2024-06-04 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 40,595 | 6.64 | 269.6K | 452,875 | — | ↗ |
| 2024-06-03 | Shawver Laura | Director | A-Award | A | Stock Option (Right to Buy) | 102,225 | 6.79 | 694.1K | 102,225 | — | ↗ |
| 2024-06-03 | Rubin Jami | Director | A-Award | A | Stock Option (Right to Buy) | 102,225 | 6.79 | 694.1K | 102,225 | — | ↗ |
| 2024-06-03 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 19,864 | 6.47 | 128.5K | 493,470 | — | ↗ |
| 2024-06-03 | Murcko Mark | Director | A-Award | A | Stock Option (Right to Buy) | 102,225 | 6.79 | 694.1K | 102,225 | — | ↗ |
| 2024-06-03 | Kathiresan Sekar | Director | A-Award | A | Stock Option (Right to Buy) | 102,225 | 6.79 | 694.1K | 102,225 | — | ↗ |
| 2024-06-03 | INGRAM DOUGLAS S | Director | A-Award | A | Stock Option (Right to Buy) | 102,225 | 6.79 | 694.1K | 102,225 | — | ↗ |
| 2024-06-03 | HILL LINDA A | Director | A-Award | A | Stock Option (Right to Buy) | 102,225 | 6.79 | 694.1K | 102,225 | — | ↗ |
| 2024-06-03 | Borisy Alexis | Director | A-Award | A | Stock Option (Right to Buy) | 102,225 | 6.79 | 694.1K | 102,225 | — | ↗ |
| 2024-04-29 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,345 | 6.38 | 8.6K | 513,334 | — | ↗ |
| 2024-04-29 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 1,695 | 6.38 | 10.8K | 339,803 | — | ↗ |
| 2024-04-29 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 2,686 | 6.38 | 17.1K | 527,427 | — | ↗ |
| 2024-04-29 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,623 | 6.38 | 10.4K | 325,767 | — | ↗ |
| 2024-03-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 298 | 7.70 | 2.3K | 514,679 | — | ↗ |
| 2024-03-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 348 | 7.70 | 2.7K | 341,498 | — | ↗ |
| 2024-03-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 765 | 7.70 | 5.9K | 530,113 | — | ↗ |
| 2024-03-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 348 | 7.70 | 2.7K | 327,390 | — | ↗ |
| 2024-01-29 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,651 | 9.64 | 15.9K | 514,977 | — | ↗ |
| 2024-01-29 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 2,005 | 9.64 | 19.3K | 341,846 | — | ↗ |
| 2024-01-29 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 3,178 | 9.64 | 30.6K | 530,878 | — | ↗ |
| 2024-01-29 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,929 | 9.64 | 18.6K | 327,738 | — | ↗ |
| 2024-01-16 | Rahmer Peter | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 516,628 | — | ↗ |
| 2024-01-16 | Patel Sanjiv | Director / Officer | A-Award | A | Common Stock | 762,360 | 0.00 | — | 764,022 | — | ↗ |
| 2024-01-16 | Catinazzo Thomas | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 343,851 | — | ↗ |
| 2024-01-16 | Bergstrom Donald A | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 534,056 | — | ↗ |
| 2024-01-16 | Adams Brian | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 329,667 | — | ↗ |
| 2023-12-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 244 | 11.51 | 2.8K | 316,628 | — | ↗ |
| 2023-12-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 294 | 11.51 | 3.4K | 143,851 | — | ↗ |
| 2023-12-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 977 | 11.51 | 11.2K | 234,056 | — | ↗ |
| 2023-12-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 294 | 11.51 | 3.4K | 129,667 | — | ↗ |
| 2023-10-30 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,354 | 6.03 | 8.2K | 316,872 | — | ↗ |
| 2023-10-30 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 1,697 | 6.03 | 10.2K | 144,145 | — | ↗ |
| 2023-10-30 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 3,451 | 6.03 | 20.8K | 235,033 | — | ↗ |
| 2023-10-30 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,632 | 6.03 | 9.8K | 129,961 | — | ↗ |
| 2023-09-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 244 | 8.38 | 2.0K | 318,226 | — | ↗ |
| 2023-09-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 294 | 8.38 | 2.5K | 145,842 | — | ↗ |
| 2023-09-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 648 | 8.38 | 5.4K | 238,484 | — | ↗ |
| 2023-09-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 294 | 8.38 | 2.5K | 131,593 | — | ↗ |
| 2023-07-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 1,352 | 11.80 | 16.0K | 316,808 | — | ↗ |
| 2023-07-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 1,693 | 11.80 | 20.0K | 146,136 | — | ↗ |
| 2023-07-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 2,683 | 11.80 | 31.7K | 237,904 | — | ↗ |
| 2023-07-28 | Adams Brian | Officer | S-Sale | D | Common Stock | 1,628 | 11.80 | 19.2K | 131,887 | — | ↗ |
| 2023-06-30 | Rahmer Peter | Officer | A-Award | A | Common Stock | 1,662 | 10.68 | 17.8K | 319,822 | — | ↗ |
| 2023-06-30 | Patel Sanjiv | Director / Officer | A-Award | A | Common Stock | 1,662 | 10.68 | 17.8K | 1,662 | — | ↗ |
| 2023-06-30 | Bergstrom Donald A | Officer | A-Award | A | Common Stock | 1,228 | 10.68 | 13.1K | 241,815 | — | ↗ |
| 2023-06-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 244 | 12.12 | 3.0K | 318,160 | — | ↗ |
| 2023-06-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 294 | 12.12 | 3.6K | 147,829 | — | ↗ |
| 2023-06-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 647 | 12.12 | 7.8K | 240,587 | — | ↗ |
| 2023-06-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 294 | 12.12 | 3.6K | 133,515 | — | ↗ |
| 2023-05-31 | Shawver Laura | Director | A-Award | A | Stock Option (Right to Buy) | 66,055 | 11.14 | 735.9K | 66,055 | — | ↗ |
| 2023-05-31 | Rubin Jami | Director | A-Award | A | Stock Option (Right to Buy) | 66,055 | 11.14 | 735.9K | 66,055 | — | ↗ |
| 2023-05-31 | Murcko Mark | Director | A-Award | A | Stock Option (Right to Buy) | 66,055 | 11.14 | 735.9K | 66,055 | — | ↗ |
| 2023-05-31 | Kathiresan Sekar | Director | A-Award | A | Stock Option (Right to Buy) | 66,055 | 11.14 | 735.9K | 66,055 | — | ↗ |
| 2023-05-31 | INGRAM DOUGLAS S | Director | A-Award | A | Stock Option (Right to Buy) | 66,055 | 11.14 | 735.9K | 66,055 | — | ↗ |
| 2023-05-31 | HILL LINDA A | Director | A-Award | A | Stock Option (Right to Buy) | 66,055 | 11.14 | 735.9K | 66,055 | — | ↗ |
| 2023-05-31 | Borisy Alexis | Director | A-Award | A | Stock Option (Right to Buy) | 66,055 | 11.14 | 735.9K | 66,055 | — | ↗ |
| 2023-05-30 | Rahmer Peter | Officer | A-Award | A | Common Stock | 161,818 | 0.00 | — | 318,404 | — | ↗ |
| 2023-05-24 | Shawver Laura | Director | G-Gift | D | Common Stock | 12,099 | 0.00 | — | 40,000 | — | ↗ |
| 2023-04-28 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 739 | 11.16 | 8.2K | 157,504 | — | ↗ |
| 2023-04-28 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 863 | 11.16 | 9.6K | 149,272 | — | ↗ |
| 2023-04-28 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 1,383 | 11.16 | 15.4K | 242,701 | — | ↗ |
| 2023-04-28 | Adams Brian | Officer | S-Sale | D | Common Stock | 863 | 11.16 | 9.6K | 134,882 | — | ↗ |
| 2023-03-27 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 297 | 15.36 | 4.6K | 158,243 | — | ↗ |
| 2023-03-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 347 | 15.36 | 5.3K | 150,135 | — | ↗ |
| 2023-03-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 763 | 15.36 | 11.7K | 244,084 | — | ↗ |
| 2023-03-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 347 | 15.36 | 5.3K | 135,745 | — | ↗ |
| 2023-02-09 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 14,000 | 20.55 | 287.7K | 0 | — | ↗ |
| 2023-02-08 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 14,000 | 20.98 | 293.7K | 0 | — | ↗ |
| 2023-02-07 | Patel Sanjiv | Director / Officer | S-Sale | D | Common Stock | 14,000 | 21.45 | 300.3K | 0 | — | ↗ |
| 2023-01-30 | Rahmer Peter | Officer | S-Sale | D | Common Stock | 740 | 21.56 | 16.0K | 158,540 | — | ↗ |
| 2023-01-30 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 864 | 21.56 | 18.6K | 150,482 | — | ↗ |
| 2023-01-30 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 1,429 | 21.56 | 30.8K | 244,847 | — | ↗ |
| 2023-01-30 | Adams Brian | Officer | S-Sale | D | Common Stock | 864 | 21.56 | 18.6K | 136,092 | — | ↗ |
| 2023-01-19 | Patel Sanjiv | Officer | M-Exempt | D | Stock Option (Right to Buy) | 28,000 | 0.00 | — | 610,779 | — | ↗ |
| 2023-01-18 | Patel Sanjiv | Officer | M-Exempt | D | Stock Option (Right to Buy) | 28,000 | 0.00 | — | 638,779 | — | ↗ |
| 2023-01-17 | Rahmer Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 97,630 | 0.00 | — | 97,630 | — | ↗ |
| 2023-01-17 | Patel Sanjiv | Officer | M-Exempt | D | Stock Option (Right to Buy) | 28,000 | 0.00 | — | 666,779 | — | ↗ |
| 2023-01-17 | Catinazzo Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 104,600 | 0.00 | — | 104,600 | — | ↗ |
| 2023-01-17 | Bergstrom Donald A | Officer | A-Award | A | Stock Option (Right to Buy) | 160,390 | 0.00 | — | 160,390 | — | ↗ |
| 2023-01-17 | Adams Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 73,220 | 0.00 | — | 73,220 | — | ↗ |
| 2023-01-12 | Adams Brian | Officer | S-Sale | D | Common Stock | 9,994 | 20.00 | 199.9K | 51,531 | — | ↗ |
| 2022-12-31 | Rahmer Peter | Officer | — | D | Stock Option (Right to Buy) | 78,540 | 20.38 | 1.60M | — | — | ↗ |
| 2022-12-27 | Catinazzo Thomas | Officer | S-Sale | D | Common Stock | 445 | 14.49 | 6.4K | 50,231 | — | ↗ |
| 2022-12-27 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 980 | 14.49 | 14.2K | 85,886 | — | ↗ |
| 2022-12-27 | Adams Brian | Officer | S-Sale | D | Common Stock | 295 | 14.49 | 4.3K | 61,525 | — | ↗ |
| 2022-11-10 | Patel Sanjiv | Officer | M-Exempt | A | Common Stock | 9,825 | 5.04 | 49.5K | 264,379 | — | ↗ |
| 2022-11-08 | Patel Sanjiv | Officer | M-Exempt | A | Common Stock | 14,000 | 4.12 | 57.7K | 268,554 | — | ↗ |
| 2022-11-01 | Bergstrom Donald A | Officer | S-Sale | D | Common Stock | 8,000 | 22.75 | 182.0K | 86,866 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.7K
Shares Outstanding
189.21M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sanjiv K. Patel, M.D. President and Chief Executive Officer | 707.8K | — | — | 3.51M | 424.7K | — | 4.65M | 75.63% | ↗ |
| 2 | 2025 | Donald Bergstrom, M.D., Ph.D. President, Research & Development | 554.3K | — | — | 1.27M | 249.4K | 14.0K | 2.09M | 60.87% | ↗ |
| 3 | 2025 | Thomas Catinazzo Chief Financial Officer | 486.1K | — | — | 874.5K | 194.4K | 13.6K | 1.57M | 55.75% | ↗ |
| 4 | 2025 | Peter Rahmer Chief Corporate Development Officer | 469.1K | — | — | 874.5K | 187.6K | 14.0K | 1.55M | 56.60% | ↗ |
| 5 | 2025 | Brian Adams Former Chief Legal Officer | 291.2K | — | — | 874.5K | — | 11.6K | 1.18M | 74.28% | ↗ |
| 6 | 2024 | Sanjiv K. Patel, M.D. President and Chief Executive Officer | 697.4K | — | 11.96M | — | 418.4K | — | 13.08M | 91.47% | ↗ |
| 7 | 2024 | Donald Bergstrom, M.D., Ph.D. President, Research & Development | 543.4K | 600.0K | 5.21M | — | 244.5K | 12.7K | 6.61M | 78.82% | ↗ |
| 8 | 2024 | Peter Rahmer Chief Corporate Development Officer | 455.4K | 600.0K | 3.71M | — | 182.2K | 12.2K | 4.96M | 74.82% | ↗ |
| 9 | 2024 | Thomas Catinazzo Chief Financial Officer | 481.3K | — | 3.71M | — | 192.5K | 13.3K | 4.40M | 84.39% | ↗ |
| 10 | 2024 | Brian R. Adams Chief Legal Officer | 455.4K | — | 3.71M | — | 182.2K | 13.8K | 4.37M | 85.08% | ↗ |
| 11 | 2024 | Brian Adams Former Chief Legal Officer | 455.4K | — | 3.71M | — | 182.2K | 13.8K | 4.37M | 85.08% | ↗ |
| 12 | 2023 | Sanjiv K. Patel, M.D. President and Chief Executive Officer | 673.8K | — | — | 18.69M | 404.3K | — | 19.77M | 94.55% | ↗ |
| 13 | 2023 | Donald Bergstrom, M.D., Ph.D. President, Research & Development | 525.0K | 600.0K | 2.93M | 4.27M | 236.3K | 7.1K | 8.57M | 84.04% | ↗ |
| 14 | 2023 | Peter Rahmer Chief Corporate Development Officer | 440.0K | — | 3.55M | 2.60M | 176.0K | 10.6K | 6.78M | 90.76% | ↗ |
| 15 | 2023 | Thomas Catinazzo Chief Financial Officer | 465.0K | — | 1.86M | 2.70M | 186.0K | 13.0K | 5.22M | 87.28% | ↗ |
| 16 | 2023 | Brian Adams Former Chief Legal Officer | 440.0K | — | 1.59M | 2.30M | 176.0K | 11.7K | 4.51M | 86.08% | ↗ |
| 17 | 2023 | Brian R. Adams Chief Legal Officer | 440.0K | — | 1.59M | 2.30M | 176.0K | 11.7K | 4.51M | 86.08% | ↗ |
| 18 | 2022 | Sanjiv K. Patel, M.D. President and Chief Executive Officer | 641.7K | — | — | 7.10M | 385.0K | — | 8.12M | 87.36% | ↗ |
| 19 | 2022 | Donald Bergstrom, M.D., Ph.D. President, Research & Development | 500.0K | — | 1.32M | 1.75M | 200.0K | 11.3K | 3.78M | 81.20% | ↗ |
| 20 | 2022 | Thomas Catinazzo Chief Financial Officer | 420.0K | — | 800.3K | 1.06M | 168.0K | 11.8K | 2.46M | 75.59% | ↗ |
| 21 | 2022 | Brian R. Adams Chief Legal Officer | 420.0K | — | 800.3K | 1.06M | 168.0K | 10.5K | 2.46M | 75.63% | ↗ |
| 22 | 2022 | Peter Rahmer Chief Corporate Development Officer | 400.0K | — | 800.3K | 1.06M | 160.0K | 10.5K | 2.43M | 76.50% | ↗ |
| 23 | 2021 | Sanjiv K. Patel, M.D. President and Chief Executive Officer | 602.6K | — | — | 7.52M | 414.3K | — | 8.53M | 88.08% | ↗ |
| 24 | 2021 | Donald Bergstrom M.D., Ph.D. President, Research & Development | 475.0K | — | 1.20M | 1.62M | 237.5K | 9.8K | 3.54M | 79.60% | ↗ |
| 25 | 2021 | Donald Bergstrom, M.D., Ph.D. President, Research & Development | 475.0K | — | 1.20M | 1.62M | 237.5K | 9.8K | 3.54M | 79.60% | ↗ |
| 26 | 2021 | Brian R. Adams Chief Legal Officer | 401.7K | — | 543.5K | 734.0K | 200.9K | 9.5K | 1.89M | 67.61% | ↗ |
| 27 | 2021 | Thomas Catinazzo Chief Financial Officer | 381.1K | — | 543.5K | 734.0K | 166.7K | 10.9K | 1.84M | 69.57% | ↗ |
| 28 | 2021 | Andy Porter Chief Administrative Officer | 412.0K | — | 479.5K | 647.5K | 206.0K | 9.6K | 1.75M | 64.23% | ↗ |
| 29 | 2020 | Sanjiv K. Patel, M.D. President and Chief Executive Officer | 585.0K | — | — | 2.59M | 402.2K | — | 3.58M | 72.40% | ↗ |
| 30 | 2020 | Donald Bergstrom M.D., Ph.D. Executive Vice President, Head of Research & Development | 440.0K | — | — | 1.34M | 220.0K | 9.8K | 2.01M | 66.66% | ↗ |
| 31 | 2020 | Brian R. Adams General Counsel | 390.0K | — | — | 714.2K | 170.6K | 7.4K | 1.28M | 55.70% | ↗ |
| 32 | 2020 | Donald Bergstrom M.D., Ph.D. President, Research & Development | 440.0K | — | — | 435.3K | 220.0K | 9.8K | 1.11M | 39.39% | ↗ |
| 33 | 2020 | Donald Bergstrom, M.D., Ph.D. President, Research & Development | 440.0K | — | — | 435.3K | 220.0K | 9.8K | 1.11M | 39.39% | ↗ |
| 34 | 2020 | Brian R. Adams Chief Legal Officer | 390.0K | — | — | 232.1K | 170.6K | 7.4K | 800.2K | 29.01% | ↗ |
| 35 | 2019 | Sanjiv K. Patel, M.D. President and Chief Executive Officer | 585.0K | — | — | 2.59M | 353.9K | — | 3.53M | 73.40% | ↗ |
| 36 | 2019 | Donald Bergstrom M.D., Ph.D. Executive Vice President, Head of Research & Development | 406.9K | — | — | 330.7K | 179.0K | — | 916.5K | 36.08% | ↗ |
| 37 | 2019 | Donald Bergstrom M.D., Ph.D. President, Research & Development | 406.9K | — | — | 330.7K | 179.0K | — | 916.5K | 36.08% | ↗ |
| 38 | 2019 | Brian R. Adams Chief Legal Officer | 356.2K | — | — | 165.3K | 98.0K | — | 619.5K | 26.69% | ↗ |
| 39 | 2019 | Brian R. Adams General Counsel | 356.2K | — | — | 165.3K | 98.0K | — | 619.5K | 26.69% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sanjiv K. Patel MBBS | Chief Executive Officer, President & Director | 1M | — |
| Donald A. Bergstrom | President of Research & Development | 817.7K | — |
| Thomas Catinazzo | Chief Financial Officer | 694.1K | male |
| Peter Rahmer | Chief Corporate Development Officer | 670.7K | male |
| Mark Murcko | Founder & Independent Director | 65.9K | — |
| Brenton Mar | Senior Vice President of Clinical Development | — | male |
| Matthew Jacobson | Founder | — | male |
| Soo-Yeun Lim | Senior Vice President & General Counsel | — | female |
| Mahesh Padval | Chief Pharmaceutical Development Officer | — | — |
| David Elliot Shaw | Founder | — | — |
| Dorothee Kern | Founder | — | female |
| Imogen Pryce | Chief Operating Officer of R&D | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-07-12 | 2023-08-13 | Daniel Goldman | NY10 | — | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RLAY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
